Role of Human Organic Cation Transporter-1 (OCT-1/SLC22A1) in Modulating the Response to Metformin in Patients with Type 2 Diabetes

Overview

Journal BMC Endocr Disord

Publisher Biomed Central

Specialty Endocrinology

Date 2022 May 26

PMID 35619086

Authors

Fizalah Kawoosa

Zafar A Shah

Shariq R Masoodi

Asif Amin

Roohi Rasool

Khalid M Fazili

Abid Hamid Dar

Asif Lone

Samir Ul Bashir

Affiliations

Soon will be listed here.

Abstract

Background: Organic cation transporter 1 primarily governs the action of metformin in the liver. There are considerable inter-individual variations in metformin response. In light of this, it is crucial to obtain a greater understanding of the influence of OCT1 expression or polymorphism in the context of variable responses elicited by metformin treatment.

Results: We observed that the variable response to metformin in the responders and non-responders is independent of isoform variation and mRNA expression of OCT-1. We also observed an insignificant difference in the serum metformin levels of the patient groups. Further, molecular docking provided us with an insight into the hotspot regions of OCT-1 for metformin binding. Genotyping of these regions revealed SNPs 156T>C and 1222A>G in both the groups, while as 181C>T and 1201G>A were found only in non-responders. The 181T>C and 1222A>G changes were further found to alter OCT-1 structure in silico and affect metformin transport in vitro which was illustrated by their effect on the activation of AMPK, the marker for metformin activity.

Conclusion: Taken together, our results corroborate the role of OCT-1 in the transport of metformin and also point at OCT1 genetic variations possibly affecting the transport of metformin into the cells and hence its subsequent action in responders and non-responders.

Citing Articles

Association of Genetic Polymorphism rs 77630697(Gly64Asp) of Multidrug and Toxin Extrusion -1 with glycemic response to metformin in patients with Type 2 Diabetes Mellitus.

Hakim Z, Hasan N, Khan A, Waheed A Pak J Med Sci. 2024; 40(6):1256-1260.

PMID: 38952525 PMC: 11190412. DOI: 10.12669/pjms.40.6.8170.

: The Two Faces of Metformin.

Goglia U, Hasballa I, Teti C, Boschetti M, Ferone D, Albertelli M Cancers (Basel). 2024; 16(7).

PMID: 38610965 PMC: 11011026. DOI: 10.3390/cancers16071287.

Coordination chemistry suggests that independently observed benefits of metformin and Zn against COVID-19 are not independent.

Lockwood T Biometals. 2024; 37(4):983-1022.

PMID: 38578560 PMC: 11255062. DOI: 10.1007/s10534-024-00590-5.

Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus.

Le J, Chen Y, Yang W, Chen L, Ye J Acta Pharm Sin B. 2024; 14(2):437-454.

PMID: 38322335 PMC: 10840401. DOI: 10.1016/j.apsb.2023.09.004.

Structural basis of promiscuous substrate transport by Organic Cation Transporter 1.

Zeng Y, Sobti M, Quinn A, Smith N, Brown S, Vandenberg J Nat Commun. 2023; 14(1):6374.

PMID: 37821493 PMC: 10567722. DOI: 10.1038/s41467-023-42086-9.

References

Shu Y, Sheardown S, Brown C, Owen R, Zhang S, Castro R . Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007; 117(5):1422-31. PMC: 1857259. DOI: 10.1172/JCI30558. View

Hayer M, Bonisch H, Bruss M . Molecular cloning, functional characterization and genomic organization of four alternatively spliced isoforms of the human organic cation transporter 1 (hOCT1/SLC22A1). Ann Hum Genet. 2001; 63(Pt 6):473-82. DOI: 10.1017/S0003480099007770. View

Florez J . Does metformin work for everyone? A genome-wide association study for metformin response. Curr Diab Rep. 2011; 11(6):467-9. DOI: 10.1007/s11892-011-0220-0. View

Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Gorboulev V, Mornhinweg E . Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics. 2002; 12(8):591-5. DOI: 10.1097/00008571-200211000-00002. View

Zhou Y, Ye W, Wang Y, Jiang Z, Meng X, Xiao Q . Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai. Int J Clin Exp Pathol. 2015; 8(8):9533-42. PMC: 4583948. View

Florez J, Jablonski K, Taylor A, Mather K, Horton E, White N . The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. Diabetes Care. 2012; 35(9):1864-7. PMC: 3425006. DOI: 10.2337/dc11-2301. View

Becker M, Visser L, van Schaik R, Hofman A, Uitterlinden A, Stricker B . Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 2009; 9(4):242-7. DOI: 10.1038/tpj.2009.15. View

Hess B, Kutzner C, van der Spoel D, Lindahl E . GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. J Chem Theory Comput. 2015; 4(3):435-47. DOI: 10.1021/ct700301q. View

van Leeuwen N, Nijpels G, Becker M, Deshmukh H, Zhou K, Stricker B . A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia. 2012; 55(7):1971-7. PMC: 3369131. DOI: 10.1007/s00125-012-2537-x. View

10.

Zhou K, Bellenguez C, Spencer C, Bennett A, Coleman R, Tavendale R . Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet. 2010; 43(2):117-20. PMC: 3030919. DOI: 10.1038/ng.735. View

11.

Mahrooz A, Parsanasab H, Hashemi-Soteh M, Kashi Z, Bahar A, Alizadeh A . The role of clinical response to metformin in patients newly diagnosed with type 2 diabetes: a monotherapy study. Clin Exp Med. 2014; 15(2):159-65. DOI: 10.1007/s10238-014-0283-8. View

12.

Hirst J, Farmer A, Ali R, Roberts N, Stevens R . Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care. 2012; 35(2):446-54. PMC: 3263873. DOI: 10.2337/dc11-1465. View

13.

Kanto K, Ito H, Noso S, Babaya N, Hiromine Y, Taketomo Y . Effects of dosage and dosing frequency on the efficacy and safety of high-dose metformin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2017; . PMC: 5934269. DOI: 10.1111/jdi.12755. View

14.

Nies A, Hofmann U, Resch C, Schaeffeler E, Rius M, Schwab M . Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS One. 2011; 6(7):e22163. PMC: 3136501. DOI: 10.1371/journal.pone.0022163. View

15.

Nies A, Koepsell H, Winter S, Burk O, Klein K, Kerb R . Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009; 50(4):1227-40. DOI: 10.1002/hep.23103. View

16.

Seitz T, Stalmann R, Dalila N, Chen J, Pojar S, Dos Santos Pereira J . Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1. Genome Med. 2015; 7(1):56. PMC: 4495841. DOI: 10.1186/s13073-015-0172-0. View

17.

Shokri F, Ghaedi H, Ghafouri Fard S, Movafagh A, Abediankenari S, Mahrooz A . Impact of ATM and SLC22A1 Polymorphisms on Therapeutic Response to Metformin in Iranian Diabetic Patients. Int J Mol Cell Med. 2016; 5(1):1-7. PMC: 4916778. View

18.

Dujic T, Zhou K, Donnelly L, Tavendale R, Palmer C, Pearson E . Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. Diabetes. 2014; 64(5):1786-93. PMC: 4452716. DOI: 10.2337/db14-1388. View

19.

Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K . Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet. 2006; 52(2):117-122. DOI: 10.1007/s10038-006-0087-0. View

20.

Emami Riedmaier A, Fisel P, Nies A, Schaeffeler E, Schwab M . Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci. 2013; 34(2):126-35. DOI: 10.1016/j.tips.2012.11.005. View